Spain-based fund targets challenges posed by aging populations and growth in chronic diseases and could grow to €150m.
Madrid-based Buenavista Equity Partners has announced the initial €100 million closing of a significant new healthcare-focused fund. A joint initiative with Columbus Venture Partners, the BV Healthcare Growth Innvierte I fund leverages the complementary expertise of both firms in private equity, venture capital and healthcare investment, and has set its sights on a maximum size of €150 million, with continued fundraising efforts underway.
Unlike yesterday’s emergence of the $40 million LongGame fund, BV Healthcare Growth Innvierte I is not exclusively focused on longevity – there are however clear signs from the fund’s leadership that aging and age-related diseases will be a top priority.
“We aim to support companies that are addressing some of the main trends in today’s society, such as precision and personalised medicine, advanced therapies, the challenges from increased longevity and the presence of chronic diseases,” said Nuria Osés, partner and head of healthcare strategy at Buenavista. “In addition to generating economic value, these companies are committed to having a positive impact on society, offering solutions that improve people’s quality of life and well-being.”
Targeting innovative healthcare companies, particularly those with low scientific and technological risk and close to commercialisation, the fund’s mission is to provide the capital, expertise and global networks necessary to accelerate the growth and scalability of these companies. Its stated focus areas include pharmaceuticals, biotech products, diagnostic solutions, precision medicine, medical equipment, AI-driven therapies, digital health solutions, industrial production scale-ups and scientific and healthcare services.
Through investments in approximately 10 to 12 companies, primarily in Spain, the fund aims to fill a critical financing gap for high-potential growth companies in the healthcare sector, with investment tickets of up to €15 million per company. A key supporter of this initiative is Spain’s Centre for Technological Development and Innovation (CDTI), which has committed up to €58 million through its Innvierte Programme, designed to foster advanced therapies and innovative drug development.
The fund’s first investment is in Syngoi, which specializes in synthetic DNA production for advanced therapies. The company’s platform enables enhanced production efficiency, higher purity levels,and reduced turnaround times, supporting applications such as mRNA vaccines, gene therapy and gene editing.
Buenavista brings vast experience as an independent asset manager in the middle-market segment, managing over €1 billion in diverse investments across private equity, infrastructure and venture capital. Columbus, known for its scientific and medical expertise, adds its impressive track record in biopharmaceutical investment, with over €400 million under management across four funds.
“The fund’s strategy responds to a profile of healthcare and biotechnology companies that are at a crucial stage of their development, seeking capital to expand their operations and that have scientifically proven and risk-free products,” said Damià Tormo, Managing Partner and co-founder of Columbus Venture Partners. “Given the lack of financing by specialised investors for this type of high-growth medical companies in Spain and in the European market, we believe that this fund fills a great gap in an area of great economic and social relevance.”
